MRK vs SLS
MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda. SLS: A late-stage biotech developer of WT1-targeting cancer immunotherapies and selective CDK9 inhibitors for various hematologic and solid tumor indications.
Side-by-side fundamentals
| Metric | MRK | SLS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $130.20 | $10.84 | |
| Market cap as of 2026-08-03 | $321.6B | $2.0B | |
| P/E as of 2026-08-03 | 36.63 | n/a | |
| PEG as of 2026-08-03 | 4.91 | n/a | |
| Net margin as of 2026-08-03 | +13.6% | -736.2% | MRK higher |
| Gross margin as of 2026-08-03 | +78.1% | +93.1% | SLS higher |
| Operating margin as of 2026-08-03 | +18.2% | -730.7% | MRK higher |
| ROE as of 2026-08-03 | +17.9% | -47.1% | MRK higher |
| ROA as of 2026-08-03 | +7.0% | -42.6% | MRK higher |
| Debt / equity as of 2026-08-03 | 1.07 | 0.00 | SLS lower |
| Revenue growth (YoY) as of 2026-08-03 | +2.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +3.1% | n/a | |
| Dividend yield as of 2026-08-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.27 | 2.50 | |
| 1-year return as of 2026-07-31 close | +66.7% | +502.2% | SLS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.